Lentinan potentiates immunity and prolongs the survival time of some patients

Anticancer Res. Jul-Aug 1997;17(4A):2751-5.

Abstract

For the selection of patients responding well to lentinan, we performed two immunological analysis of patients. Flow cytometric analysis was obtained from peripheral blood lymphocytes; the patients who had greater than 2.5 ratio of [CD11(-) CD8(+)/CD11(+) CD8(+) after treatment]/[CD11(-) CD8(+)/CD11(+) CD8(+) before treatment] at 10 days after lentinan administration showed prolonged survival. The analysis of the- levels of soluble factors such as IL-6, sIL-6R, TNF-alpha, G-CSF, sICAM-1, IAP, and PGE2 and the decreasing levels of G-CSF, IL-6, and PGE2 after lentinan administration had a statistically significant correlation with the ratio of [CD4(+) CD29(+)/CD4(+) CD29(-) after treatment]/[(CD4(+) CD29(+)/CD4(+)CD29(-) before treatment]. The decrease in IL-6, G-CSF, and PGE2 levels after lentinan administration indicated an increase in immunine potential. From these results, we belive that patients with over 2.5-fold increase in [CD11(-) CD8(+)/CD11(+) CD8(+) after treatment]/[CD11(-) CD8(+)/CD11(+) CD8(+) before treatment] and showing a decrease in IL-6, G-CSF, and PGE2 levels after lentinan administration should continue treatment with lentinan for a long period.

Publication types

  • Clinical Trial

MeSH terms

  • Adjuvants, Immunologic / therapeutic use*
  • Antineoplastic Agents / administration & dosage
  • Combined Modality Therapy
  • Cytokines / metabolism
  • Dinoprostone / blood
  • Female
  • Gallbladder Neoplasms / therapy*
  • Humans
  • Immunophenotyping
  • Lentinan / therapeutic use*
  • Lymphocyte Subsets / cytology
  • Male
  • Middle Aged
  • Pancreatic Neoplasms / therapy*
  • Survival Analysis

Substances

  • Adjuvants, Immunologic
  • Antineoplastic Agents
  • Cytokines
  • Lentinan
  • Dinoprostone